HIV/AIDS Trials

Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.

Page 1 of 1 | Results 1 - 2 of 2

GEMINI 1 - A Phase III, randomised, double-blind, multicentre, parallel- group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults - 204861

The purpose of this study is to compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily to the DTG plus Tenofovir [TDF]/Emtricitabine [FTC] fixed dose combination [FDC] administered once daily in human immunodeficiency virus (HIV) 1 infected adult subjects that have not previously received antiretroviral therapy. The study is designed to demonstrate the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC.

Lead Researcher: Dr. Daniel Skiest

Condition/Disease: Infection, HIV

Location:

Baystate Medical Center 759 Chestnut Street Springfield, MA 01199

REPRIEVE (A5332) - Randomized Trial to Prevent Vascular Events in HIV

The purpose of this study is to test the efficacy of 4 mg Pitavastatin daily on cardiovascular-related events among HIV-1 infected adults.

Lead Researcher: Daniel J. Skiest, MD

Condition/Disease: HIV, Heart

Location:

Baystate Infectious Diseases Clinical Research

3300 Main Street

Springfield, MA 01199

Page 1 of 1 | Results 1 - 2 of 2